T. Rowe Price Group, Inc.
TROWT. Rowe Price Group, Inc. is coiled. The quarters are improving, yet the P/BV sits at the 8th percentile of its own 5-year range — the business is moving before the market.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (1 weeks in) while the P/BV sits at the 8th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +26.5% year on year, with the the net margin at 32.5%. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
T. Rowe Price Group, Inc. trades at $102, building a base and 1 weeks into that stage. That is −1.4% against its own 200-day average. It sits at 50% of a 52-week range of $86 to $119. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is building a base — week 1 of stage 1. At $102 it trades −1.4% versus its 200-day average and sits at 50% of its 52-week range ($86–$119).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +40% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-08-28) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each $1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.
T. Rowe Price Group, Inc. trades at 2.0× P/BV, near the bottom of its own range — cheaper only 8% of the time. Its long-run median P/BV is 2.6×, measured across 5.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/BV of 2.0× is near the bottom of its own range — cheaper only 8% of the time, against a long-run median of 2.6× measured over 5.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year book value grew while the price moved −3.4% — price and book moved together, holding the multiple in its range.
The price move, decomposed: over 5y, of the −13.7%/yr price move, ~+8.4%/yr came from book-value growth and ~−22.1 pp from the multiple (compressing). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the book-value line underneath it, not the multiple.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
T. Rowe Price Group, Inc. reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROE at 17.8% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +3.1% | +4.0% | — | — |
| Profit | +0.0% | +10.3% | — | — |
| EPS | +1.0% | +11.3% | — | — |
| Stock price | −3.4% | −2.2% | −13.7% | +4.3% |
4-Factor Sector Score
55.6/100 — rank 5 of 29 in Asset Management · 80% evidence confidence
T. Rowe Price Group, Inc. scores 55.6 out of 100 against the 29 companies it is compared with in Asset Management, ranking 5. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16 + 20.1 + 14.7 + 4.8 = 55.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fees from its businesses.
T. Rowe Price Group, Inc. reported $1.9 B of income in the Jun 26 quarter, +11.0% year on year. That is the 4th straight quarter of year-on-year growth. Over 4 years it has compounded at −1.2% a year. The last full year, FY25, came in at $7.3 B. The last four reported quarters add to $7.6 B.
FY25 revenue came in at $7.3 B (+3.1% on the year), capping 4 years at −1.2% compound. The latest quarter (Jun 26) printed $1.9 B, +11.0% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +7.1% growth against the decade's −1.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.1% over the last 4 quarters against +5.7%/yr over the last 8 — stabilising; TTM profit +9.0% vs +6.9%/yr — stabilising.
Net margin Net margin — what the bank keeps of every $100 of revenue after every cost, provision and tax. With big fee businesses in the mix, it is the cleanest margin we can read for this bank.
T. Rowe Price Group, Inc.'s net margin is 32.5% in the Jun 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 23.4% to 39.1%. The current quarter sits inside that band.
The latest quarter's net margin is 32.5%, +4.0 pp against the same quarter a year ago. Across 5 fiscal years the net margin has ranged 23.4%–39.1%.
Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
T. Rowe Price Group, Inc. earned $0.6 B of net profit in the Jun 26 quarter, +26.5% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $2.0 B. The 4-year compound rate is −9.2%. That is 32.5% of the quarter's revenue. The same quarter a year earlier earned $0.5 B.
Jun 26 profit was $0.6 B, +26.5% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $2.0 B (+0.0%), and the 4-year compound rate is −9.2%.
Why profit moved: revenue contributed +11.0% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +8.8% vs revenue +7.1%. Profit and revenue are moving roughly in step.
Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.
Loan-book quality history is not available for T. Rowe Price Group, Inc., so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.
We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.
Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.
The loan book We read the loan book through revenue — when the book and the businesses grow, revenue grows with them. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.
T. Rowe Price Group, Inc.'s revenue grew +3.1% in FY25 to $7.3 B, so the book is growing. The latest quarter ran +11.0% year on year. The net margin on that income is 32.5%, +4.0 percentage points against a year ago.
FY25 revenue was $7.3 B, +3.1% on the year, and the latest quarter ran +11.0% year on year. The net margin on that revenue is 32.5% this quarter (+4.0 pp YoY) — growth with a widening margin on it.
The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — with quarterly loan-quality numbers missing here, revenue growth and margin are the two we watch.
Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.
T. Rowe Price Group, Inc. earns a return on equity of 17% in FY25. Its trough over the ladder below was 16% in FY22. On the asset side every $100 of the balance sheet earned about $10.66, which is the return before leverage is applied.
FY25 ROE came in at 17%, recovered from a FY22 trough of 16%. On assets, the latest reading is about 10.66% — every $100 the bank deploys earns roughly $10.66 a year. That clears the bar a bank must beat for its book value to compound.
Why ROE moved: profit compounded −9.2% a year over 4 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
T. Rowe Price Group, Inc. paid $5.14 per share over the last four reported quarters. The most recent declaration was $1.30 for Jun 26. Against the current price of $102 that is a trailing yield of 5.02%, measured on dividends already paid rather than on a forecast.
T. Rowe Price Group, Inc. paid $5.14 per share across the last four reported quarters, most recently $1.30 for Jun 26. Against the current price of $102 the trailing twelve months work out to 5.02% — trailing dividends measured against today's price, not a forward estimate.
Debt
For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.
A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
12.5% of T. Rowe Price Group, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 15.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 12.5% of the float is sold short, and at typical trading volumes it would take about 15.6 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
T. Rowe Price Group, Inc.: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.
The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Victory Capital Holdings, Inc.VCTR | 67.4/100Favorable setup76% evidence | LEADER | 25.0/35 Income 64.1% · PAT 29.1% 71% evidence | 16.1/25 ROA 3.6% · ROE 6.4% · GNPA — 68% evidence | 7.6/20 P/BV 2.29× · P/BV÷ROE 0.36 70% evidence | 18.7/20 RS sector 22.7% · RS bench 24.4% · 1Y 54.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 16.1 + 7.6 + 18.7 = 67.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Principal Financial Group, Inc.PFG | 62.3/100Mixed-positive evidence80% evidence | LEADER | 22.5/35 Income 3.7% · PAT 36.9% 81% evidence | 11.2/25 ROA 0.4% · ROE 13.3% · GNPA — 68% evidence | 14.1/20 P/BV 1.81× · P/BV÷ROE 0.14 70% evidence | 14.5/20 RS sector 11.4% · RS bench 13.1% · 1Y 42.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 11.2 + 14.1 + 14.5 = 62.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3SEI Investments CompanySEIC | 59.2/100Mixed-positive evidence60% evidence | LEADER | 18.0/35 Income — · PAT — 26% evidence | 17.0/25 ROA 5.2% · ROE 7.7% · GNPA — 68% evidence | 6.0/20 P/BV 4.21× · P/BV÷ROE 0.55 70% evidence | 18.2/20 RS sector 9.7% · RS bench 11.2% · 1Y 20.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 17 + 6 + 18.2 = 59.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4Ameriprise Financial, Inc.AMP | 57.0/100Mixed-positive evidence64% evidence | BREAKING OUT | 18.3/35 Income 10.6% · PAT 22.4% 62% evidence | 16.4/25 ROA — · ROE 17.9% · GNPA — 34% evidence | 7.3/20 P/BV 6.37× · P/BV÷ROE 0.36 70% evidence | 15.0/20 RS sector 2.6% · RS bench 3.9% · 1Y 10.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 16.4 + 7.3 + 15 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5T. Rowe Price Group, Inc.this pageTROW | 55.6/100Mixed-positive evidence80% evidence | ASLEEP | 16.0/35 Income 7% · PAT 9.1% 81% evidence | 20.1/25 ROA 12% · ROE 16.2% · GNPA — 68% evidence | 14.7/20 P/BV 2× · P/BV÷ROE 0.12 70% evidence | 4.8/20 RS sector -8.6% · RS bench -7.3% · 1Y -3.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 20.1 + 14.7 + 4.8 = 55.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Brookfield Asset Management Ltd.BAM | 54.8/100Mixed-positive evidence80% evidence | ASLEEP | 28.5/35 Income 31.9% · PAT 32.8% 81% evidence | 17.9/25 ROA 5.6% · ROE 10.2% · GNPA — 68% evidence | 4.4/20 P/BV 9.53× · P/BV÷ROE 0.94 70% evidence | 4.0/20 RS sector -16.5% · RS bench -15.4% · 1Y -24.7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 17.9 + 4.4 + 4 = 54.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -16.5% and the one-year return is -24.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Northern Trust CorporationNTRS | 54.8/100Mixed-positive evidence64% evidence | FADING | 22.9/35 Income 15.7% · PAT 29.4% 62% evidence | 12.7/25 ROA — · ROE 6% · GNPA — 34% evidence | 7.1/20 P/BV 2.37× · P/BV÷ROE 0.4 70% evidence | 12.1/20 RS sector 6% · RS bench 7.6% · 1Y 34.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 12.7 + 7.1 + 12.1 = 54.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8BlackRock, Inc.BLK | 53.6/100Mixed-positive evidence80% evidence | ASLEEP | 17.2/35 Income 26.5% · PAT 2.7% 81% evidence | 18.3/25 ROA 3.4% · ROE 14.9% · GNPA — 68% evidence | 12.8/20 P/BV 2.31× · P/BV÷ROE 0.15 70% evidence | 5.3/20 RS sector -10.4% · RS bench -9.2% · 1Y -9.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 18.3 + 12.8 + 5.3 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Affiliated Managers Group, Inc.AMG | 52.3/100Mixed-positive evidence60% evidence | FADING | 20.2/35 Income — · PAT — 26% evidence | 14.8/25 ROA 1.6% · ROE 6.1% · GNPA — 68% evidence | 6.4/20 P/BV 2.94× · P/BV÷ROE 0.48 70% evidence | 10.9/20 RS sector 4.4% · RS bench 5.9% · 1Y 41.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 14.8 + 6.4 + 10.9 = 52.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10StepStone Group Inc.STEP | 52.3/100Thin evidence · provisional55% evidence | TURNING | 23.3/35 Income 69.7% · PAT — 45% evidence | 13.1/25 ROA 6.9% · ROE 0.5% · GNPA — 68% evidence | 9.8/20 P/BV -9.31× · P/BV÷ROE — 10% evidence | 6.1/20 RS sector -18.5% · RS bench -17.7% · 1Y -25.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 23.3 + 13.1 + 9.8 + 6.1 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Corebridge Financial, Inc.CRBG | 52.2/100Thin evidence · provisional55% evidence | BREAKING OUT | 19.1/35 Income 14.6% · PAT -71.3% 45% evidence | 4.8/25 ROA 0% · ROE -0.5% · GNPA — 68% evidence | 9.8/20 P/BV 1.01× · P/BV÷ROE — 10% evidence | 18.5/20 RS sector 9.4% · RS bench 10.7% · 1Y 7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 4.8 + 9.8 + 18.5 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Blackstone Inc.BX | 51.3/100Mixed-positive evidence80% evidence | ASLEEP | 23.4/35 Income 17.2% · PAT 19.1% 81% evidence | 17.2/25 ROA 5% · ROE 10.8% · GNPA — 68% evidence | 4.5/20 P/BV 9.82× · P/BV÷ROE 0.91 70% evidence | 6.2/20 RS sector -15.2% · RS bench -14.3% · 1Y -34.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 23.4 + 17.2 + 4.5 + 6.2 = 51.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15.2% and the one-year return is -34.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 13Janus Henderson Group plcJHG | 51.0/100Mixed-positive evidence70% evidence | 20.6/35 Income 24.5% · PAT 100% 71% evidence | 11.7/25 ROA 1.2% · ROE 1.9% · GNPA — 68% evidence | 5.5/20 P/BV 1.53× · P/BV÷ROE 0.81 70% evidence | 13.2/20 RS sector 5.3% · RS bench 0.6% · 1Y 28.9%0 of 1 week ahead to 2026-07-02 70% evidence | |
| Exact sum: 20.6 + 11.7 + 5.5 + 13.2 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14State Street CorporationSTT | 49.7/100Mixed-negative evidence80% evidence | LEADER | 19.3/35 Income 12.3% · PAT 21.3% 81% evidence | 8.9/25 ROA 0.3% · ROE 3.9% · GNPA — 68% evidence | 6.9/20 P/BV 1.68× · P/BV÷ROE 0.43 70% evidence | 14.6/20 RS sector 17.3% · RS bench 19% · 1Y 61.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 8.9 + 6.9 + 14.6 = 49.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Invesco Ltd.IVZ | 48.9/100Mixed-negative evidence60% evidence | BREAKING OUT | 19.2/35 Income — · PAT — 26% evidence | 10.8/25 ROA 1% · ROE 2.4% · GNPA — 68% evidence | 7.4/20 P/BV 0.94× · P/BV÷ROE 0.39 70% evidence | 11.5/20 RS sector 4.1% · RS bench 5.4% · 1Y 33.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 10.8 + 7.4 + 11.5 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Equitable Holdings, Inc.EQH | 45.5/100Mixed-negative evidence76% evidence | BREAKING OUT | 11.8/35 Income -23.4% · PAT -126% 71% evidence | 12.3/25 ROA 0.3% · ROE 24.1% · GNPA — 68% evidence | 3.6/20 P/BV 38.27× · P/BV÷ROE 1.59 70% evidence | 17.8/20 RS sector 9.3% · RS bench 10.6% · 1Y -0.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 12.3 + 3.6 + 17.8 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 10.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17Franklin Resources, Inc.BEN | 44.1/100Mixed-negative evidence60% evidence | FADING | 17.1/35 Income — · PAT — 26% evidence | 8.6/25 ROA 0.4% · ROE 1.8% · GNPA — 68% evidence | 5.7/20 P/BV 1.44× · P/BV÷ROE 0.8 70% evidence | 12.7/20 RS sector 9.3% · RS bench 11% · 1Y 34%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 8.6 + 5.7 + 12.7 = 44.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Blue Owl Capital Inc.OWL | 42.4/100Mixed-negative evidence60% evidence | BREAKING OUT | 19.5/35 Income — · PAT — 26% evidence | 12.3/25 ROA 1.6% · ROE 1.9% · GNPA — 68% evidence | 4.6/20 P/BV 2.94× · P/BV÷ROE 1.55 70% evidence | 6.0/20 RS sector -22.9% · RS bench -22.3% · 1Y -46.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 12.3 + 4.6 + 6 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Raymond James Financial, Inc.RJF | 41.6/100Mixed-negative evidence80% evidence | FADING | 15.6/35 Income 10.5% · PAT 8.1% 81% evidence | 10.9/25 ROA 0.7% · ROE 4.8% · GNPA — 68% evidence | 6.7/20 P/BV 2.3× · P/BV÷ROE 0.48 70% evidence | 8.4/20 RS sector -5.5% · RS bench -4.3% · 1Y -5.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 10.9 + 6.7 + 8.4 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Ares Management CorporationARES | 40.7/100Mixed-negative evidence80% evidence | ASLEEP | 21.7/35 Income 24% · PAT 32.9% 81% evidence | 10.2/25 ROA 0.7% · ROE 3.6% · GNPA — 68% evidence | 3.4/20 P/BV 6.38× · P/BV÷ROE 1.77 70% evidence | 5.4/20 RS sector -15.3% · RS bench -14.5% · 1Y -32.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 10.2 + 3.4 + 5.4 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Blackstone Secured Lending FundBXSL | 39.3/100Mixed-negative evidence62% evidence | TURNING | 9.5/35 Income -22.6% · PAT -19.1% 55% evidence | 11.9/25 ROA — · ROE 3.4% · GNPA — 34% evidence | 8.6/20 P/BV 0.9× · P/BV÷ROE 0.27 70% evidence | 9.3/20 RS sector -8.3% · RS bench -7% · 1Y -10.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.5 + 11.9 + 8.6 + 9.3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22TPG Inc.TPG | 38.8/100Mixed-negative evidence64% evidence | BREAKING OUT | 17.1/35 Income 11.5% · PAT 100% 71% evidence | 4.2/25 ROA -0.8% · ROE -3.4% · GNPA — 68% evidence | 9.4/20 P/BV 5.73× · P/BV÷ROE — 10% evidence | 8.1/20 RS sector -14.5% · RS bench -13.8% · 1Y -27.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 4.2 + 9.4 + 8.1 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Apollo Global Management, Inc.APO | 37.8/100Mixed-negative evidence80% evidence | ASLEEP | 18.3/35 Income 41.2% · PAT -17.5% 81% evidence | 9.4/25 ROA 0.5% · ROE 5.5% · GNPA — 68% evidence | 5.8/20 P/BV 3.24× · P/BV÷ROE 0.59 70% evidence | 4.3/20 RS sector -9.9% · RS bench -8.8% · 1Y -14%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 9.4 + 5.8 + 4.3 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24KKR & Co. Inc.KKR | 34.2/100Adverse evidence80% evidence | ASLEEP | 17.4/35 Income 31.1% · PAT 13.5% 81% evidence | 6.9/25 ROA 0.1% · ROE 1.5% · GNPA — 68% evidence | 4.2/20 P/BV 2.65× · P/BV÷ROE 1.77 70% evidence | 5.7/20 RS sector -17.2% · RS bench -16.4% · 1Y -35%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 6.9 + 4.2 + 5.7 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Blue Owl Capital CorporationOBDC | 31.2/100Adverse evidence62% evidence | TURNING | 9.0/35 Income -11% · PAT -50.5% 55% evidence | 9.9/25 ROA — · ROE 0.5% · GNPA — 34% evidence | 4.8/20 P/BV 0.77× · P/BV÷ROE 1.53 70% evidence | 7.5/20 RS sector -12.8% · RS bench -11.6% · 1Y -20.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 9.9 + 4.8 + 7.5 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Brookfield CorporationBN | 26.2/100Adverse evidence80% evidence | ASLEEP | 12.9/35 Income 1.8% · PAT 21% 81% evidence | 8.7/25 ROA 0.7% · ROE 0.4% · GNPA — 68% evidence | 3.8/20 P/BV 2.24× · P/BV÷ROE 5.6 70% evidence | 0.8/20 RS sector -22.7% · RS bench -21.6% · 1Y -22.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 8.7 + 3.8 + 0.8 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27The Carlyle Group Inc.CG | 22.8/100Adverse evidence64% evidence | ASLEEP | 5.9/35 Income -28.9% · PAT -44% 71% evidence | 5.9/25 ROA 0.3% · ROE -2.1% · GNPA — 68% evidence | 9.6/20 P/BV 3.22× · P/BV÷ROE — 10% evidence | 1.4/20 RS sector -28.5% · RS bench -27.6% · 1Y -41.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 5.9 + 5.9 + 9.6 + 1.4 = 22.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Pershing Square Inc.PS | 57.5/100Thin evidence · provisional42% evidence | BREAKING OUT | 29.2/35 Income 68.8% · PAT 100% 71% evidence | 8.3/25 ROA 1% · ROE -35.8% · GNPA — 68% evidence | 10.0/20 P/BV — · P/BV÷ROE — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 8 weeks ahead 0% evidence |
| Exact sum: 29.2 + 8.3 + 10 + 10 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Ares Capital CorporationARCC | 42.3/100Thin evidence · provisional46% evidence | TURNING | 16.5/35 Income — · PAT — 10% evidence | 10.4/25 ROA — · ROE 1.2% · GNPA — 34% evidence | 5.9/20 P/BV 0.96× · P/BV÷ROE 0.8 70% evidence | 9.5/20 RS sector -8% · RS bench -6.7% · 1Y -10.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 10.4 + 5.9 + 9.5 = 42.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is T. Rowe Price Group, Inc.'s stock price today?
T. Rowe Price Group, Inc. trades at $102, −3.4% over the past year. The company is valued at $22.0 B. The stock sits at 50% of its 52-week range of $86–$119, −1.4% versus its 200-day average. On the tape, the price is building a base, 1 weeks in. — as of 17 September 2026.
What were T. Rowe Price Group, Inc.'s latest quarterly results?
T. Rowe Price Group, Inc. reported total income of $1.9 B and net profit of $0.6 B for the Jun 26 quarter. Income rose 11.0% and profit rose 26.5% year on year. Earnings per share were $2.88. The net margin was 32.5%, 4.0 pp higher than a year earlier. — as of 17 September 2026.
What is T. Rowe Price Group, Inc.'s revenue?
T. Rowe Price Group, Inc. reported revenue of $1.9 B in the Jun 26 quarter, +11.0% year on year. For the full FY25 fiscal year, revenue was $7.3 B (+3.1%). Over the last 4 years revenue compounded at −1.2% a year. — as of 17 September 2026.
What is T. Rowe Price Group, Inc.'s profit?
T. Rowe Price Group, Inc. earned $0.6 B of net profit in the Jun 26 quarter, +26.5% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $2.0 B. The net margin ran 32.5% in the latest quarter. — as of 17 September 2026.
What is T. Rowe Price Group, Inc.'s market cap?
T. Rowe Price Group, Inc.'s market capitalisation is $22.0 B at a stock price of $102. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is T. Rowe Price Group, Inc.'s P/BV ratio?
T. Rowe Price Group, Inc. trades at a P/BV of 2.0×, at the 8th percentile of its own 5-year range, against a long-run median of 2.6×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does T. Rowe Price Group, Inc. pay a dividend?
Yes — T. Rowe Price Group, Inc. declared $1.30 per share for Jun 26, and $5.14 per share across the last four reported quarters. — as of 17 September 2026.
What is T. Rowe Price Group, Inc.'s dividend per share?
T. Rowe Price Group, Inc.'s most recently declared dividend is $1.30 per share for Jun 26, giving $5.14 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is T. Rowe Price Group, Inc.'s dividend yield?
T. Rowe Price Group, Inc.'s trailing dividend yield is 5.02%: $5.14 declared per share across the last four reported quarters, against a share price of $102. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is T. Rowe Price Group, Inc. overvalued?
On its own history, T. Rowe Price Group, Inc. looks cheap: its P/BV of 2.0× has been cheaper only 8% of the time in 5 years (long-run median 2.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is T. Rowe Price Group, Inc. growing?
Yes — T. Rowe Price Group, Inc. is growing: latest-quarter revenue +11.0% year on year, profit +26.5%, and the net margin +4.0 pp at 32.5%. The 4-year compound rates are −1.2% (revenue) and −9.2% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is T. Rowe Price Group, Inc. performing?
T. Rowe Price Group, Inc. is building a base, 1 weeks in. Its latest quarter's income rose 11.0% and profit rose 26.5% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is T. Rowe Price Group, Inc. in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROE at 17.8% and holding. The read comes from the last 12 quarters of growth (revenue growth +7.1% latest, profit growth +9.0% latest, eps growth +11.4% latest) plus the ROE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is T. Rowe Price Group, Inc. in an uptrend?
No — the price is building a base (week 1 of stage 1), trading −1.4% versus its 200-day average and at 50% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is T. Rowe Price Group, Inc. beating the market?
Not lately — on a trailing-13-week view T. Rowe Price Group, Inc. is currently behind the S&P 500 (3 weeks and counting; last ahead the week of 2026-08-28), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +40% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will T. Rowe Price Group, Inc.'s stock price go up?
This page publishes no price forecast for T. Rowe Price Group, Inc. What it measures instead: the stock price is $102, the price is building a base 1 weeks in. Its P/BV of 2.0× sits at the 8th percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against T. Rowe Price Group, Inc.?
Yes — short interest is 12.5% of T. Rowe Price Group, Inc.'s tradable float, about 15.6 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Where is T. Rowe Price Group, Inc. in its business cycle?
T. Rowe Price Group, Inc.'s FY25 net margin was 27.9%, against a 5-year band of 23.4%–39.1%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 32.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the T. Rowe Price Group, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is T. Rowe Price Group, Inc. a stock worth studying right now?
This is not investment advice. The machine read: T. Rowe Price Group, Inc. is coiled. The quarters are improving, yet the P/BV sits at the 8th percentile of its own 5-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!